Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

242
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
242
Data Reporting and Recording01:24

Data Reporting and Recording

5.4K
Reporting and recording are crucial in data documentation. The timely, thorough, and accurate documentation of facts is essential when recording patient data. Failure to record findings during an assessment or interpretation of a problem will result in loss of information and make the patient document unreliable. The reader is left with general impressions if the information is not specific. A recording is documenting data of the individual's health information in a traceable, secure, and...
5.4K
Types of Reports I: Hands-off Report01:25

Types of Reports I: Hands-off Report

1.5K
A hand-off report, also known as a change-of-shift report, is a crucial nursing process that ensures the smooth transition of patient care responsibilities between nursing staff.
Following are the key components and categories of hand-off reports:
Purpose and Process:
1.5K
Types of Reports II: Incident or Occurrence Report01:21

Types of Reports II: Incident or Occurrence Report

1.2K
An Incident or Occurrence Report in a healthcare setting is a crucial document used to record any unexpected occurrence that may or may not have affected a patient, employee, or visitor. Such reports are critical to improving patient safety and include all details leading up to and including the event.
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
1.2K
Types of Reports III: Telephone and Verbal Reports01:26

Types of Reports III: Telephone and Verbal Reports

1000
Telephone and Verbal Reports in healthcare settings are two communication methods for conveying therapeutic instructions from healthcare providers to nurses or other healthcare staff.
Here's an overview of each type:
Telephone Orders
1000
Reporter Genes02:11

Reporter Genes

13.1K
Reporter genes are a type of protein-coding gene that are often tagged to a gene of interest. Once inside a target cell, reporter genes usually produce visually identifiable characteristics like fluorescence and luminescence when expressed along with the gene of interest. Thus, reporter genes “report” the presence or absence of genes of interest in an organism, determine the gene expression pattern, or track the physical location of a DNA segment or protein in the cell.
13.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Basis of Core Fucosylation-Dependent Modulation of IgG1 Fc-CD16a Binding.

bioRxiv : the preprint server for biology·2026
Same author

Leveraging analytical and bioprocess platforms for biological product development and commercialization - A meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
Same author

Analyses of Exosomal HER2 in Breast Cancer and the Effect of Respective Exosome-Immune Complexes on Trastuzumab-Based Immunotherapy.

International journal of molecular sciences·2025
Same author

Discoloration source and control of a biotechnological drug product manufactured using a high titer production process.

Journal of pharmaceutical sciences·2025
Same author

A vision for patient-centric specifications for biologicals.

Biologicals : journal of the International Association of Biological Standardization·2024
Same author

Patient-Centric Quality Standards.

Journal of pharmaceutical sciences·2024

Related Experiment Video

Updated: Jan 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing

Stephan Krause1, Emanuela Lacana2, Joel Welch2

  • 1AstraZeneca Biologics, 1 Medimmune Way, Gaithersburg, MD 20878; Stephan.Krause@astrazeneca.com.

PDA Journal of Pharmaceutical Science and Technology
|April 21, 2019
PubMed
Summary

This workshop report details challenges and best practices for developing biosimilars, focusing on regulatory perspectives, development hurdles, and demonstrating analytical similarity for successful marketing applications.

Keywords:
Continuous processingDownstream processingFDAFacility risk mitigationHealth CanadaNovel format moleculesPEIRegulatory agenciesRegulatory perspectiveResin lifetimeStrategySubmissionUpstream processingViral Clearance SymposiumViral clearanceViral safety

More Related Videos

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K
Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes
07:38

Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes

Published on: September 1, 2020

5.6K

Related Experiment Videos

Last Updated: Jan 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K
Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes
07:38

Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes

Published on: September 1, 2020

5.6K

Area of Science:

  • Biopharmaceutical Development
  • Regulatory Science
  • Analytical Chemistry

Background:

  • Biosimilar development presents significant challenges for both sponsors and regulatory agencies.
  • A dedicated workshop was convened to address current best practices and existing challenges in biosimilar development.
  • The workshop brought together 140 representatives from regulatory agencies and the biopharmaceutical industry.

Purpose of the Study:

  • To summarize key discussions, outcomes, and recommendations from the PDA Biosimilars Workshop.
  • To provide consolidated answers to case studies addressing current challenges in biosimilar development and regulatory submission.
  • To share insights on regulatory perspectives, technical challenges, and analytical similarity demonstration for biosimilars.

Main Methods:

  • The workshop featured presentations from agency and industry experts, followed by concurrent roundtable discussions.
  • Case studies were developed to focus on difficult situations encountered in biosimilar development and regulatory processes.
  • Discussions covered regulatory expectations for Chemistry, Manufacturing, and Controls (CMC), data quality, control strategies, and statistical tools.

Main Results:

  • Session 1 (Regulatory Perspective) outlined expectations for CMC information in biosimilar marketing applications.
  • Session 2 (Challenges in Biosimilar Development) addressed technical hurdles, data quality, control strategies, and candidate selection.
  • Session 3 (Demonstrating Analytical Similarity) explored the application of statistical tools and practical challenges in establishing analytical similarity.

Conclusions:

  • Significant challenges remain in the development and licensing of biosimilars, requiring collaborative solutions.
  • The workshop provided practical insights and potential solutions for sponsors and agencies navigating the biosimilar pathway.
  • Effective demonstration of analytical similarity and robust CMC information are critical for successful biosimilar applications.